Besides pharmacological ORAI1 inhibitors, alternative strategies employed ORAI1-specific antibodies to reduce autoimmune response in ex vivo T cells from humans and mice (75–78), and the ORAI1-specific siRNA SYL116011 is used in preclinical studies for allergic conjunctivitis (79, 80). This evidence concerns the gene ORAI1 and atopic conjunctivitis.